Analysts expect Helix Energy Solutions Group, Inc. (NYSE:HLX) to report $-0.06 EPS on April, 23.They anticipate $0.05 EPS change or 45.45% from last quarter’s $-0.11 EPS. After having $-0.01 EPS previously, Helix Energy Solutions Group, Inc.’s analysts see 500.00% EPS growth. The stock increased 1.05% or $0.06 during the last trading session, reaching $5.79. About 1.80 million shares traded or 33.50% up from the average. Helix Energy Solutions Group, Inc. (NYSE:HLX) has declined 16.14% since March 31, 2017 and is downtrending. It has underperformed by 27.69% the S&P500.
ZEALAND PHARMA A/S ORDINARY SHARES DENM (OTCMKTS:ZLDPF) had a decrease of 9.17% in short interest. ZLDPF’s SI was 59,400 shares in March as released by FINRA. Its down 9.17% from 65,400 shares previously. With 100 avg volume, 594 days are for ZEALAND PHARMA A/S ORDINARY SHARES DENM (OTCMKTS:ZLDPF)’s short sellers to cover ZLDPF’s short positions. The SI to ZEALAND PHARMA A/S ORDINARY SHARES DENM’s float is 0.26%. It closed at $16.12 lastly. It is down 0.00% since March 31, 2017 and is . It has underperformed by 11.55% the S&P500.
Among 11 analysts covering Helix Energy Solutions (NYSE:HLX), 7 have Buy rating, 2 Sell and 2 Hold. Therefore 64% are positive. Helix Energy Solutions had 30 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Hold” rating by Piper Jaffray given on Friday, December 22. On Tuesday, April 12 the stock rating was upgraded by Credit Suisse to “Outperform”. The firm has “Outperform” rating by Iberia Capital Partners given on Wednesday, February 24. The rating was maintained by Cowen & Co on Wednesday, August 30 with “Buy”. As per Tuesday, July 26, the company rating was upgraded by Clarksons Platou. On Tuesday, December 29 the stock rating was maintained by Cowen & Co with “Market Perform”. The rating was maintained by Cowen & Co on Friday, October 6 with “Buy”. The firm has “Market Perform” rating given on Monday, September 21 by Cowen & Co. Cowen & Co maintained the stock with “Buy” rating in Friday, July 7 report. The rating was maintained by Cowen & Co on Thursday, January 11 with “Buy”.
Helix Energy Solutions Group, Inc., together with its subsidiaries, provides specialty services to the offshore energy industry primarily in the Gulf of Mexico, North Sea, the Asia Pacific, and West Africa regions. The company has market cap of $857.38 million. It operates through three divisions: Well Intervention, Robotics, and Production Facilities. It has a 28.95 P/E ratio. The firm engineers, manages, and conducts well construction, intervention, and abandonment activities in water depths ranging from 200 to 10,000 feet; and operates remotely operated vehicles , trenchers, and ROVDrills for offshore construction, maintenance, and well intervention services.
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide medicines in Denmark. The company has market cap of $483.76 million. The firm markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. It currently has negative earnings. The Company’s products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes.
The post Helix Energy Solutions Group, Inc. (HLX) EPS Estimated At $-0.06; ZEALAND PHARMA A/S ORDINARY SHARES DENM (ZLDPF) Shorts Decreased By 9.17% appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/03/31/helix-energy-solutions-group-inc-hlx-eps-estimated-at-0-06-zealand-pharma-a-s-ordinary-shares-denm-zldpf-shorts-decreased-by-9-17/
No comments:
Post a Comment